355 related articles for article (PubMed ID: 10964781)
21. Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis.
Schnölzer M; Rackwitz HR; Gustchina A; Laco GS; Wlodawer A; Elder JH; Kent SB
Virology; 1996 Oct; 224(1):268-75. PubMed ID: 8862421
[TBL] [Abstract][Full Text] [Related]
22. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
23. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
Goodenow MM; Bloom G; Rose SL; Pomeroy SM; O'Brien PO; Perez EE; Sleasman JW; Dunn BM
Virology; 2002 Jan; 292(1):137-49. PubMed ID: 11878916
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the pH-dependencies of the association and dissociation kinetics of HIV-1 protease inhibitors.
Gossas T; Danielson UH
J Mol Recognit; 2003; 16(4):203-12. PubMed ID: 12898670
[TBL] [Abstract][Full Text] [Related]
25. In vitro cleavage of eIF4GI but not eIF4GII by HIV-1 protease and its effects on translation in the rabbit reticulocyte lysate system.
Ohlmann T; Prévôt D; Décimo D; Roux F; Garin J; Morley SJ; Darlix JL
J Mol Biol; 2002 Apr; 318(1):9-20. PubMed ID: 12054764
[TBL] [Abstract][Full Text] [Related]
26. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
Côté HC; Brumme ZL; Harrigan PR
J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
[TBL] [Abstract][Full Text] [Related]
27. Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo.
Ermolieff J; Lin X; Tang J
Biochemistry; 1997 Oct; 36(40):12364-70. PubMed ID: 9315877
[TBL] [Abstract][Full Text] [Related]
28. Design of peptidomimetic inhibitors of aspartic protease of HIV-1 containing -Phe Psi Pro- core and displaying favourable ADME-related properties.
Frecer V; Berti F; Benedetti F; Miertus S
J Mol Graph Model; 2008 Oct; 27(3):376-87. PubMed ID: 18678515
[TBL] [Abstract][Full Text] [Related]
29. Substrate recognition in HIV-1 protease: a computational study.
Perez MA; Fernandes PA; Ramos MJ
J Phys Chem B; 2010 Feb; 114(7):2525-32. PubMed ID: 20121080
[TBL] [Abstract][Full Text] [Related]
30. Systematic profiling of substrate binding response to multidrug-resistant mutations in HIV-1 protease: Implication for combating drug resistance.
Lv Y; Li J; Fang J; Jiao X; Yan L; Shan B
J Mol Graph Model; 2017 Jun; 74():83-88. PubMed ID: 28371730
[TBL] [Abstract][Full Text] [Related]
31. Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases.
Beck ZQ; Lin YC; Elder JH
J Virol; 2001 Oct; 75(19):9458-69. PubMed ID: 11533208
[TBL] [Abstract][Full Text] [Related]
32. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(1):157-66. PubMed ID: 15751773
[TBL] [Abstract][Full Text] [Related]
33. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
Clemente JC; Hemrajani R; Blum LE; Goodenow MM; Dunn BM
Biochemistry; 2003 Dec; 42(51):15029-35. PubMed ID: 14690411
[TBL] [Abstract][Full Text] [Related]
34. Autoprocessing of HIV-1 protease is tightly coupled to protein folding.
Louis JM; Clore GM; Gronenborn AM
Nat Struct Biol; 1999 Sep; 6(9):868-75. PubMed ID: 10467100
[TBL] [Abstract][Full Text] [Related]
35. A catalogue of putative HIV-1 protease host cell substrates.
Impens F; Timmerman E; Staes A; Moens K; Ariën KK; Verhasselt B; Vandekerckhove J; Gevaert K
Biol Chem; 2012 Sep; 393(9):915-31. PubMed ID: 22944692
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins.
Cameron CE; Grinde B; Jentoft J; Leis J; Weber IT; Copeland TD; Wlodawer A
J Biol Chem; 1992 Nov; 267(33):23735-41. PubMed ID: 1331099
[TBL] [Abstract][Full Text] [Related]
37. The inhibition of HIV-1 protease by interface peptides.
Schramm HJ; Billich A; Jaeger E; Rücknagel KP; Arnold G; Schramm W
Biochem Biophys Res Commun; 1993 Jul; 194(2):595-600. PubMed ID: 8343146
[TBL] [Abstract][Full Text] [Related]
38. Contribution of the Gag-Pol transframe domain p6* and its coding sequence to morphogenesis and replication of human immunodeficiency virus type 1.
Paulus C; Ludwig C; Wagner R
Virology; 2004 Dec; 330(1):271-83. PubMed ID: 15527852
[TBL] [Abstract][Full Text] [Related]
39. The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.
Velazquez-Campoy A; Kiso Y; Freire E
Arch Biochem Biophys; 2001 Jun; 390(2):169-75. PubMed ID: 11396919
[TBL] [Abstract][Full Text] [Related]
40. A survey of furin substrate specificity using substrate phage display.
Matthews DJ; Goodman LJ; Gorman CM; Wells JA
Protein Sci; 1994 Aug; 3(8):1197-205. PubMed ID: 7987214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
